U.S., March 17 -- ClinicalTrials.gov registry received information related to the study (NCT07473102) titled 'PET Imaging of MMP Activation in AAA: First-in-Human Evaluation' on Dec. 03, 2025.
Brief Summary: A first-in-human evaluation of [64Cu]-RYM2 with PET/CT will be performed to: a) assess its safety, biodistribution, and radiation dosimetry in normal volunteers (WU) and; b) in AAA patients undergoing surgery (WU and Yale), evaluate radiotracer pharmacodynamics and correlate PET imaging characteristics (WU) with ex vivo tissue measurements (Yale).
Study Start Date: Nov. 03, 2025
Study Type: INTERVENTIONAL
Condition:
Abdominal Aortic Aneurysm
Intervention:
DRUG: Cu-64-RYM2
PET/CT scan
DRUG: PET imaging using Cu-64
PET/CT at dif...